Life sciences laboratory

Corporate Development & Strategic Advisory for Life Sciences

A Trusted Partner for Your Most Consequential Decisions

Senior advisory for biotechnology, pharmaceutical, medtech, and diagnostics companies - across financing, valuation, licensing, and strategic decisions.

Book a Discovery Call Explore Services
Biotechnology· Pharma· Medtech· Diagnostics· Health Technology

Services

Four Practice Areas.

01

Financial Modeling & Valuation

Analytical rigor at the core of every engagement.

Every major corporate event - financing, licensing, acquisition, or IPO - begins and ends with a defensible view of value. For clinical-stage companies, value is driven by pipeline, IP, and regulatory milestones, which demands specialized methodologies that generalist advisors often apply incorrectly.

  • Integrated financial model (P&L, balance sheet, cash flow, scenarios)
  • Asset & enterprise valuation (DCF, risk-adjusted NPV, comparable transactions, sum-of-parts)
  • Cap-table & SAFE/convertible modeling
  • IP & pipeline valuation
  • Due-diligence & M&A valuation
02

Business Planning & Fundraising Strategy

A well-sequenced capital strategy materially improves both the odds and the terms of a raise.

Investors expect a coherent story integrating science, regulatory pathway, and financial strategy. Companies that approach fundraising reactively consistently accept lower valuations and less favorable terms.

  • Business plan development
  • Fundraising strategy & round execution
  • Investor package & data room
  • Non-dilutive & grant funding (SBIR/STTR, NIH)
  • IPO / SPAC advisory
03

Business Development & Licensing

Deal terms compound over the full life of an agreement.

For many life-sciences companies, out-licensing and strategic partnerships are the primary path to commercialization. Negotiating them well requires benchmarking and structuring expertise most companies lack in-house. Our senior advisor brings direct experience structuring a $100M+ licensing transaction.

  • Out-licensing strategy & structuring
  • IP valuation for negotiations
  • Term-sheet advisory
  • Strategic partner identification & outreach
  • M&A advisory (buy- or sell-side)
04

AI Transformation for Biopharma & Medtech

Closing the gap between AI ambition and measurable results.

Clinical-stage companies carry disproportionate operational complexity but lack the resources to deploy AI well. Generic AI consultancies don't understand the biotech operating model; sector advisors typically can't implement. Vantagebios does both.

  • AI readiness assessment
  • Finance & IR workflow automation
  • Business-development intelligence
  • Legal & cap-table intelligence
  • Fractional AI strategy leadership

Process

How We Work With Clients.

01

Discovery Call

A complimentary, no-obligation conversation to understand your priorities, constraints, timeline, and decision context.

02

Tailored Scope & Roadmap

We design a customized engagement around your goals and current obstacles, whether a focused single-service project or a phased multi-area advisory program.

03

Market Fit Strategy

We identify the most suitable path for your stage, resources, stakeholders, and market reality, then shape the financing, valuation, partnership, business planning, or AI adoption work around it.

04

Decision-Ready Delivery

We deliver investor-grade models, valuation analyses, strategic recommendations, and bilingual materials prepared for board review, investor diligence, and partnering discussions.

All engagements are governed by a mutual NDA prior to any exchange of information. Deliverables are provided in professional, editable formats.

Begin the Conversation →

Why Vantagebios

What clients value most.

Science-to-Capital Translation

We turn complex science, IP, clinical data, and regulatory milestones into a financial story investors and partners can understand.

Defensible Valuation Discipline

We build model-backed valuation, cap-table, and scenario analyses so you can defend pricing, dilution, and deal terms with confidence.

Capital & Strategic Transaction Solutions Across Markets

We help you evaluate financing, licensing, partnership, M&A, IPO/SPAC, and restructuring options across Taiwan, APAC, and the U.S.

Deep Sector & Deal Experience

Our senior advisor brings life-sciences operating, fundraising, licensing, SEC/SPAC/IPO, and board-level experience to high-stakes decisions.

Integrated Expertise, Bilingual

You work directly with a focused team fluent across science, finance, and operations, with Mandarin-English cross-border communication.

Partner-Ready, Investor-Grade Execution

We package your asset, data, valuation logic, investor materials, data room, and negotiation framework so investors and strategic partners can diligence efficiently and engage with confidence.

The Team

Experienced. Global. Integrated.

An integrated, execution-oriented advisory team fluent across science, finance, and operations: bridging R&D, finance, legal, and business-development priorities into one coherent strategy.

Dr. Hsiou-Chi Liou

Senior Advisor

PhD (Harvard) · CFA Charterholder

20+ years in biomedical R&D, drug discovery, corporate development, SEC/SPAC/IPO execution, $100M+ licensing, and public company board governance.

Advises on corporate development, valuation defense, fundraising, licensing, transaction strategy, and board-level decision making.

Melody Yeh

Financial Analyst

MS (NYU)

BlackRock and Citi experience across institutional asset management, corporate banking, financial modeling, capital markets materials, and portfolio analytics.

Owns financial model execution, valuation analysis, cap table scenarios, fundraising analytics, and investor-facing financial narratives.

Hans Tao

AI Systems Architect

MS (Georgia Tech)

Microsoft enterprise solution engineering across AI agent deployment, workflow automation, software development, and technical implementation for enterprise clients.

Leads AI-enabled execution, workflow implementation, technical buildout, and systems that support faster advisory delivery.

FAQ

Frequently Asked Questions

How do engagements begin?

Every engagement starts with a complimentary discovery call to assess fit, scope, and near-term priorities — no commitment required. All engagements are covered by a mutual NDA prior to any exchange of information.

Can I engage a single service, or must I take a full program?

Services are independently selectable. You may engage a single item or combine several across categories to build a program tailored to a specific financing round, licensing negotiation, or strategic decision. Scope is always agreed in advance in a written statement of work.

Do you work with early-stage companies?

Yes. Many engagements begin at the pre-seed or seed stage, where getting the financial model and fundraising narrative right from the start has the most impact. Advisory scope is calibrated to the company's stage.

Do you advise companies in Taiwan and Asia-Pacific?

Yes. Vantagebios advises companies in the US, Taiwan, and across Asia-Pacific. Dr. Liou works in both English and Mandarin Chinese.

How is confidentiality maintained?

All engagements are governed by a mutual NDA from the first conversation. Deliverables are provided in professional, editable formats for internal use only.

Do you provide investment advice or securities recommendations?

No. Advisory services cover financial modeling, valuation, business strategy, and transaction structuring. This does not constitute investment advice, securities recommendations, or regulated financial advice.

Articles

Perspectives on
Life Sciences Strategy

View All Articles →

March 5, 2025

Pipeline Prioritization as a Capital Allocation Discipline

Choosing which programs to advance is a capital allocation decision, not just a scientific one. Financial modeling gives boards the framework to make these decisions with discipline.

Read →

February 10, 2025

What Licensing Negotiations Need Before Term-Sheet Discussions

Most licensing discussions fall apart before they start because neither party has done the analytical work to understand what the asset is worth under different deal structures.

Read →

January 15, 2025

How Biotech Founders Should Think About Valuation Before a Financing Round

Valuation in biotech is not just a negotiation number—it is a signal to investors about how you understand your own risk profile, milestones, and capital needs.

Read →

Begin the Conversation

Ready to bring structure to your next consequential decision?

We welcome an initial, no-obligation discussion of your priorities and how we can help. Engagements begin with a complimentary discovery call.

  • No commitment required
  • ·
  • Mutual NDA from day one
  • ·
  • English & Mandarin Chinese
Book a Discovery Call Send an Email

contact@vantagebios.com · vantagebios.com